Therefore, our findings show that VEGF‐targeted therapy impaired tumor growth in all PDOX tested, but only increased the invasive capacity of a specific subset of ccRCC tumors, indicating a patient‐specific pro‐invasive response. This evidence concerns the gene VEGFA and nonpapillary renal cell carcinoma.